Genmab AS (GEN):企業の財務・戦略的SWOT分析

◆英語タイトル:Genmab AS (GEN) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15903
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Genmab AS (GEN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company’s marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Its products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS Key Recent Developments

Mar 29,2019 Constitution of the board of directors in Genmab and grant of restricted stock units and warrants to employees in Genmab
Mar 11,2019 Genmab names Marisol Peron as head of communications and investor relations
Feb 25,2019 Genmab Announces Positive Topline Results in Phase III Study of Subcutaneous Daratumumab in Multiple Myeloma
Feb 20,2019 Genmab 2018 annual report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Genmab A/S – Key Facts
Genmab A/S – Key Employees
Genmab A/S – Key Employee Biographies
Genmab A/S – Major Products and Services
Genmab A/S – History
Genmab A/S – Company Statement
Genmab A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Genmab A/S – Business Description
R&D Overview
Genmab A/S – Corporate Strategy
Genmab A/S – SWOT Analysis
SWOT Analysis – Overview
Genmab A/S – Strengths
Genmab A/S – Weaknesses
Genmab A/S – Opportunities
Genmab A/S – Threats
Genmab A/S – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Genmab A/S, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 29, 2019: Constitution of the board of directors in Genmab and grant of restricted stock units and warrants to employees in Genmab
Mar 11, 2019: Genmab names Marisol Peron as head of communications and investor relations
Feb 25, 2019: Genmab Announces Positive Topline Results in Phase III Study of Subcutaneous Daratumumab in Multiple Myeloma
Feb 20, 2019: Genmab 2018 annual report
Nov 26, 2018: Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
Nov 14, 2018: Genmab reports financial results for the first nine months of 2018
Nov 01, 2018: Genmab Announces Data to be Presented at 2018 ASH Annual Meeting
Oct 29, 2018: Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
Oct 21, 2018: Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Genmab A/S, Key Facts
Genmab A/S, Key Employees
Genmab A/S, Key Employee Biographies
Genmab A/S, Major Products and Services
Genmab A/S, History
Genmab A/S, Subsidiaries
Genmab A/S, Key Competitors
Genmab A/S, Ratios based on current share price
Genmab A/S, Annual Ratios
Genmab A/S, Annual Ratios (Cont...1)
Genmab A/S, Interim Ratios
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Genmab A/S, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Genmab A/S, Performance Chart (2014 - 2018)
Genmab A/S, Ratio Charts
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Genmab AS (GEN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Blue Dolphin Energy Company (BDCO):企業財務及び戦略的SWOT分析
    Summary Blue Dolphin Energy Company (Blue Dolphin) is an oil and gas company that refines and markets petroleum products. The company own and operate pipeline assets and have leasehold interests in oil and gas properties. It acquires, develops and explores oil and gas properties. Blue Dolphin offers …
  • Aegis Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Aegis Therapeutics LLC (Aegis Therapeutics) is a drug-delivery and drug-formulation technologies company that commercializes drug delivery and protein stabilization technologies through product specific licenses to pharmaceutical and biopharmaceutical companies. The company offers Intravail, …
  • COWI AS:企業の戦略的SWOT分析
    COWI AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Inform Genomics, Inc.:企業のM&A・提携動向(医療機器分野)
    Summary Inform Genomics, Inc. (Inform Genomics) is a pharmaceutical company that develops genomic-based personalized medicine products for cancer and supportive care. The company’s OnPART is a medicinal product used for the treatment of decisions in patients who receive chemotherapy for colorectal, …
  • SAS AB:企業の戦略・SWOT・財務情報
    SAS AB - Strategy, SWOT and Corporate Finance Report Summary SAS AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Celon Pharma SA (CLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Celon Pharma SA (Celon Pharma), subsidiary of Glatton Sp zoo, is an integrated pharmaceutical company that carries out research and develops new medicines. The company provides product portfolio such as Aromek, Salmex, Valzek, Lazivir, Bosentan Celon, Donepex and Ketrel, among others. It pri …
  • Consort Medical plc (CSRT):企業のM&A・提携動向(医療機器分野)
    Summary Consort Medical plc (Consort Medical) is a global contract development and manufacturing organization focusing on medical device technologies for drug delivery. It develops, manufactures and markets high volume disposable medical devices for drug delivery and point-of-care (POC) diagnostics. …
  • Hologic Inc (HOLX)-製薬・医療分野:企業M&A・提携分析
    Summary Hologic Inc (Hologic) is a medical device company. It develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products. The company offers diagnostic products to aid in the diagnosis of human diseases and screen donated human blood; a broad portfolio of …
  • Systems Consultants Services Ltd:企業の戦略・SWOT・財務分析
    SummarySystems Consultants Services Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the com …
  • MKS Instruments, Inc. (MKSI):企業の財務及び戦略的SWOT分析
    MKS Instruments, Inc. (MKSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Calmare Therapeutics Incorporated (CTTC):企業のM&A・提携動向(医療機器分野)
    Summary Calmare Therapeutics Incorporated (CTT), formerly known as Competitive Technologies, Inc. is a medical device company that identifies, develops and commercializes product technologies in life, electronic, nano, and physical sciences areas. The company provides distribution, patent and techno …
  • Coca-Cola HBC-Srbija d.o.o.:企業の戦略・SWOT・財務情報
    Coca-Cola HBC-Srbija d.o.o. - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola HBC-Srbija d.o.o. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Jamaica Public Service Company Limited:企業のM&A・提携動向(発電分野)
    Summary Jamaica Public Service Company Limited (JPS) is an integrated electric utility which generates, procures, transmits, distributes and supplies power. It produces electricity from heavy fuel oil, automotive diesel oil, and hydro sources; and procures energy from independent power producers. Th …
  • Samsung Electronics Co., Ltd.:企業の戦略・SWOT・財務分析
    Samsung Electronics Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Electronics Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Zafgen Inc (ZFGN):企業の財務・戦略的SWOT分析
    Summary Zafgen Inc (Zafgen) is a clinical-stage biopharmaceutical company that develops transformative therapies for patients affected by a range of metabolic diseases. Its pipeline product portfolio includes ZGN-1061, a small molecule MetAP2 inhibitor being developed for patients with type 2 diabet …
  • Allocate Software plc (formerly Manpower Software plc):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Allocate Software plc (formerly …
  • One Lambda, Inc.:企業のM&A・提携動向(医療機器分野)
    Summary One Lambda, Inc. (One Lambda), a subsidiary of Thermo Fisher Scientific Inc., is a medical equipment company that develops and distributes histocompatibility typing tests and antibody detection products. The company offers products such as HLA tissue typing trays, monoclonal typing trays, ce …
  • Jack Henry and Associates, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Jack Henry and Associates, Inc. …
  • Indowind Energy Limited (INDOWIND):企業概要、財務及び戦略的SWOT分析
    Summary Indowind Energy Limited (IEL) is a renewable energy company. The company develops wind farms for sale, manages the wind assets, and generates green power for sale to utilities and corporate. Its services include green power sale, project management services, asset management services, and va …
  • QD Vision, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' QD Vision, Inc. Mergers and Acq …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆